tadalafil has been researched along with Familial Primary Pulmonary Hypertension in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (92.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crook, S; Dorn, ML; Frank, B; Hite, MD; Issapour, A; Ivy, DD; Krishnan, US; Rosenzweig, EB | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Fujitomi, E; Ohara, N; Sato, M; Tsukamoto, K; Yamamura, A; Yamamura, H | 1 |
| Cohen, JL; Krishnan, US; Nees, SN; Rosenzweig, EB; Valencia, GA | 1 |
| Doran, AK; Hill, W; Shapiro, S; Traiger, G; Zhang, L | 1 |
| Chalam, KV; Grover, S; Murthy, RK; Perez, L; Priluck, JC | 1 |
| Beheshtian, E; Sabri, MR | 1 |
| Channick, R; Klinger, JR; Preston, I | 1 |
| Ioakeimidis, N; Kostis, JB | 1 |
| Hayashi, H; Hirai, K; Itoh, K; Ono, Y; Todoroki, K; Tomatsuri, M; Toyo'oka, T; Yamada, H; Yamada, Y; Yokoyama, Y | 1 |
| Cleary, KL; Običan, SG | 1 |
| Gazzana, MB; Knorst, MM | 1 |
| Bauer, F; Bergot, E; Bertoletti, L; Bourdin, A; Bouvaist, H; Chabannes, C; Chaouat, A; Cottin, V; Dauphin, C; De Groote, P; Humbert, M; Jaïs, X; Montani, D; Sattler, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Dardi, F; Denton, CP; Esler, A; Galiè, N; Harmon, C; Li, B; Manes, A; Mazzanti, G; Palazzini, M; Varanese, L | 1 |
| Levin, YD; White, RJ | 1 |
| Klinger, JR | 1 |
| Allanore, Y | 1 |
| Carbognani, D; Chachques, JC; Dai, G; Feng, M; Lila, N; Nour, S; Wu, G; Yang, D | 1 |
| Lam, D; Mathai, SC; Puhan, MA; Wise, RA | 1 |
| Ahmad, S; Brown, AW; Lemma, M; Nathan, SD; Shlobin, OA; Weir, N | 1 |
| Barst, RJ; Beardsworth, A; Botros, FT; Brundage, BH; Chan, M; Galiè, N; Ghofrani, HA; Oudiz, RJ; Simonneau, G | 1 |
| Ji, YQ; Liu, CP; Lu, WX; Zeng, Q; Zhang, WH; Zhang, YJ | 1 |
| Bregel, D; Kaiser, R; Kraemer, T; Rust, KY; Wilkens, H; Wilske, J | 1 |
| Schwarz, ER; Udeoji, DU | 1 |
7 review(s) available for tadalafil and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Topics: Administration, Oral; Carbolines; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Topics: Animals; Carbolines; Cardiovascular Diseases; Cardiovascular System; Erectile Dysfunction; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2014 |
Pulmonary arterial hypertension in pregnancy.
Topics: Anesthesia, Obstetrical; Bosentan; Carbolines; Directive Counseling; Epoprostenol; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Iloprost; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pregnancy, High-Risk; Prognosis; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbolines; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Kidney; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Signal Transduction; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents | 2011 |
Tadalafil for the treatment of pulmonary arterial hypertension.
Topics: Blood Pressure; Carbolines; Cyclic GMP; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Natriuretic Peptides; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Treatment Outcome; Vasodilator Agents | 2011 |
Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Arterial Pressure; Carbolines; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Tadalafil; Treatment Outcome | 2013 |
2 trial(s) available for tadalafil and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
Topics: Connective Tissue Diseases; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Physical Examination; Tadalafil; Treatment Outcome; Vasodilator Agents | 2017 |
Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Bosentan; Carbolines; Double-Blind Method; Drug Administration Schedule; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Sulfonamides; Tadalafil; Treatment Outcome; Vasodilator Agents | 2012 |
16 other study(ies) available for tadalafil and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Tadalafil; Treatment Outcome | 2022 |
Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro.
Topics: Apoptosis; Cell Line; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 5; Down-Regulation; Familial Primary Pulmonary Hypertension; Humans; Myocytes, Smooth Muscle; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Tadalafil | 2017 |
Sildenafil Use in Children with Pulmonary Hypertension.
Topics: Adolescent; Bronchopulmonary Dysplasia; Child; Child, Preschool; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Sildenafil Citrate; Tadalafil; Treatment Outcome; Vasodilator Agents | 2019 |
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbolines; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Tadalafil for benign prostatic hyperplasia.
Topics: Adult; Carbolines; Drug Approval; Erectile Dysfunction; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2013 |
Acute, bilateral, concurrent central retinal artery occlusion in sickle cell disease after use of tadalafil (Cialis).
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Carbolines; Familial Primary Pulmonary Hypertension; Female; Fluorescein Angiography; Humans; Hypertension, Pulmonary; Papilledema; Phosphodiesterase 5 Inhibitors; Retinal Artery Occlusion; Tadalafil; Tomography, Optical Coherence | 2013 |
Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Carbolines; Child; Child, Preschool; Dose-Response Relationship, Drug; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Oxygen Consumption; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Wedge Pressure; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Walking; Young Adult | 2014 |
Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Topics: Bosentan; Carbolines; Child; Child, Preschool; Chromatography, Liquid; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Infant; Male; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Tandem Mass Spectrometry | 2014 |
Therapy for pulmonary arterial hypertension: approved dosages should be prescribed in clinical practice.
Topics: Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Humans; Pulmonary Wedge Pressure; Tadalafil; Vasodilator Agents | 2015 |
Initial dual oral combination therapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Diethylpropion; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Safety; Phenylpropionates; Pyridazines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2016 |
Phosphodiesterase 5 inhibitors in vascular systemic disorders.
Topics: Animals; Carbolines; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vascular Diseases; Vasodilator Agents | 2012 |
Intrapulmonary shear stress enhancement: a new therapeutic approach in pulmonary arterial hypertension.
Topics: Analysis of Variance; Animals; Biomarkers; Blotting, Western; Carbolines; Cardiac Output; Disease Models, Animal; Extracorporeal Circulation; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Nitric Oxide Synthase Type III; Shear Strength; Swine; Tadalafil; Vascular Resistance | 2012 |
The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Carbolines; Data Interpretation, Statistical; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Outcome Assessment, Health Care; Phosphodiesterase 5 Inhibitors; Reproducibility of Results; Tadalafil; Treatment Outcome | 2012 |
Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations.
Topics: Adult; Aged; Carbolines; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Purines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents; Young Adult | 2012 |
Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Arterioles; Carbolines; Disease Models, Animal; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Inflammation Mediators; Interleukin-6; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Simvastatin; Tadalafil; Time Factors; Vasodilator Agents | 2012 |
Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
Topics: Adult; Aged; Antihypertensive Agents; Biotransformation; Carbolines; Chromatography, High Pressure Liquid; Drug Monitoring; Familial Primary Pulmonary Hypertension; Forensic Toxicology; Humans; Hypertension, Pulmonary; Imidazoles; Limit of Detection; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Reproducibility of Results; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride | 2012 |